Drugs in MeSH Category Phosphodiesterase Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abraxis Pharm	AMINOPHYLLINE	aminophylline	INJECTABLE;INJECTION	084568-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Fresenius Kabi Usa	DIPYRIDAMOLE	dipyridamole	INJECTABLE;INJECTION	074956-001	Sep 30, 1998		DISCN	No	No
Hospira	AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER	aminophylline	INJECTABLE;INJECTION	018924-003	Dec 12, 1984		DISCN	No	No
Morton Grove	AMINOPHYLLINE	aminophylline	SOLUTION;ORAL	088156-001	Dec 5, 1983		DISCN	No	No

Phosphodiesterase Inhibitors Market Analysis and Financial Projection

The global phosphodiesterase (PDE) inhibitors market demonstrates robust growth driven by therapeutic advancements and expanding applications, while the patent landscape reveals intense innovation across neurological, cardiovascular, and inflammatory indications.

Market Dynamics

The PDE inhibitors market is projected to grow from USD 3.78 billion in 2023 to USD 6.01–6.92 billion by 2030–2032, driven by a 6.0–6.88% CAGR[1][4][5]. Key factors include:

• Aging populations: Over 30% of PDE5 inhibitor use targets age-related erectile dysfunction in men, with 30 million global users[5].
• Disease prevalence: PDE inhibitors address pulmonary hypertension (40% of cases), COPD (5 million patients on PDE4 inhibitors), and cardiovascular disorders (15% of clinical trials)[4].
• Cost dynamics: Branded PDE5 inhibitors average $60/dose, while generics cost $20/dose, fueling accessibility[4].

Market segmentation highlights:	Segment	Share (2019)	Key Applications
PDE5 inhibitors	30%	Erectile dysfunction, pulmonary hypertension[5]
PDE4 inhibitors	28%	COPD, dermatological conditions[5]

---

Patent Landscape

Pharmaceutical companies and academia are actively securing IP across PDE subtypes:

1. PDE10A inhibitors: Patents target neurological disorders (e.g., schizophrenia, Huntington’s disease) with compounds like heterocyclic derivatives (ZA201402966B)[6].
2. PDE4 inhibitors: Over 500 clinical trials in 2023 explored combinations to reduce side effects (e.g., Roflumilast + antiemetics)[16][18].
3. PDE5 innovations: Novel formulations for Parkinson’s disease (WO2001078711A3) and pediatric pulmonary hypertension[5][11].

Emerging trends:

• Combination therapies: 20% of recent patents pair PDE inhibitors with agents mitigating side effects (e.g., nausea)[16].
• Drug repurposing: PDE4 inhibitors like Apremilast expanded into autoimmune and dermatologic indications[17].

---

Strategic Challenges and Opportunities

• Side effects: Dose-limiting issues (e.g., nausea for PDE4 inhibitors) drive 43% of recent patents toward improved safety profiles[16][18].
• Neurological focus: 25% of patents since 2020 target Alzheimer’s and dementia via PDE2/9 modulation[10][14].

"The relentless march of time brings with it a silver tsunami – a rapidly aging global population that stands as a primary driver of the PDE inhibitor market." – Industry Report[4].

This landscape underscores PDE inhibitors’ role in addressing unmet needs across therapeutic areas, with innovation balancing efficacy and tolerability.

References

1. https://www.databridgemarketresearch.com/reports/global-pde-inhibitors-market
2. https://www.ncbi.nlm.nih.gov/books/NBK559276/
3. https://www.technavio.com/report/phosphodiesterase-pde-inhibitors-market-industry-analysis
4. https://virtuemarketresearch.com/report/phosphodiesterase-inhibitor-market
5. https://www.marketdataforecast.com/market-reports/pde-inhibitors-market-revenue
6. https://patents.google.com/patent/ZA201402966B/en26
7. https://www.ncbi.nlm.nih.gov/books/NBK549843/
8. https://en.wikipedia.org/wiki/List_of_MeSH_codes_(D27)
9. https://www.tandfonline.com/doi/abs/10.4155/ppa.15.11
10. https://www.tandfonline.com/doi/full/10.1080/13543776.2024.2412577?src=
11. https://patents.google.com/patent/WO2001078711A3/en
12. https://intbrazjurol.com.br/pdf/vol47n02/vol47n02_2021.pdf
13. https://aem-prod.oklahoma.gov/content/dam/ok/en/okhca/docs/about/boards-and-committees/dur/2024/june/06122024%20DUR%20Packet.pdf
14. https://www.biorxiv.org/content/10.1101/2023.02.10.527980v3.full-text
15. https://patents.google.com/patent/WO2008035316A3/en
16. https://patents.justia.com/patent/20220304935
17. https://patents.google.com/patent/WO2010074783A1/en
18. https://patents.google.com/patent/US8470821B2/en